In addition to anti-TNF agents, other novel biological agents have been implemented in IBD therapy, such as ustekinumab (UST) and vedolizumab (VDZ), which work against anti-IL12/23 and anti-α4β7 integrin, respectively [15,16]. Here, TNF is linked to inflammatory bowel disease.